Literature DB >> 29966195

Rapidly Progressive Alzheimer's Disease in Two Distinct Autopsy Cohorts.

Jagan A Pillai, Brian S Appleby, Jiri Safar, James B Leverenz.   

Abstract

BACKGROUND: A rapidly progressive phenotype of Alzheimer's disease (AD) has been described in some prion disease cohorts. Limited information regarding rapidly progressive AD (rpAD) is available from longitudinal national cohorts.
OBJECTIVE: To compare the clinical characteristics of rpAD in two different national cohorts.
METHODS: A retrospective analysis was performed on AD subjects with available neuropathology in the National Alzheimer's Coordinating Center (NACC) database and among neuropathologically characterized AD cases from the National Prion Disease Pathology Surveillance Center (NPDPSC) that were evaluated for suspected prion disease. In the NACC cohort, rpAD was delineated by the lower 10th percentile of follow up duration from pre-dementia to death duration among subjects meeting pathological diagnosis of AD.
RESULTS: rpAD from the NPDPSC had a shorter mean symptom duration than the NACC identified rpAD cases (11.6 months versus 62.4 months) and were also younger at the time of their death (60.0 versus 81.8 years). NACC identified rpAD subjects, beginning from a predementia stage, had slower rate of MMSE change per year than NPDPSC cases (2.5 versus 6.0 points).
CONCLUSIONS: rpAD constitute an important subset of AD subjects in whom a rapid course of symptomatic clinical decline is noted, as confirmed in both national cohorts. rpAD was best characterized by survival time (≤3 years), as there were clear differences between the rpAD cohorts in terms of symptom duration, age at death, and MMSE change per year, likely due to the strong selection biases. rpAD could shed light on the biology of rate of progression in AD.

Entities:  

Keywords:  Alzheimer’s disease; dementia; rapidly progressive dementia; rate of decline

Mesh:

Year:  2018        PMID: 29966195      PMCID: PMC6487475          DOI: 10.3233/JAD-180155

Source DB:  PubMed          Journal:  J Alzheimers Dis        ISSN: 1387-2877            Impact factor:   4.472


  5 in total

Review 1.  Recent update on the heterogeneity of the Alzheimer's disease spectrum.

Authors:  Kurt A Jellinger
Journal:  J Neural Transm (Vienna)       Date:  2021-12-17       Impact factor: 3.575

2.  Distinct populations of highly potent TAU seed conformers in rapidly progressing Alzheimer's disease.

Authors:  Chae Kim; Tracy Haldiman; Sang-Gyun Kang; Lenka Hromadkova; Zhuang Zhuang Han; Wei Chen; Frances Lissemore; Alan Lerner; Rohan de Silva; Mark L Cohen; David Westaway; Jiri G Safar
Journal:  Sci Transl Med       Date:  2022-01-05       Impact factor: 19.319

3.  Inflammatory pathway analytes predicting rapid cognitive decline in MCI stage of Alzheimer's disease.

Authors:  Jagan A Pillai; James Bena; Gurkan Bebek; Lynn M Bekris; Aaron Bonner-Jackson; Lei Kou; Akshay Pai; Lauge Sørensen; Mads Neilsen; Stephen M Rao; Mark Chance; Bruce T Lamb; James B Leverenz
Journal:  Ann Clin Transl Neurol       Date:  2020-07-07       Impact factor: 4.511

4.  Prion protein oligomers cause neuronal cytoskeletal damage in rapidly progressive Alzheimer's disease.

Authors:  Mohsin Shafiq; Saima Zafar; Neelam Younas; Aneeqa Noor; Berta Puig; Hermann Clemens Altmeppen; Matthias Schmitz; Jakob Matschke; Isidre Ferrer; Markus Glatzel; Inga Zerr
Journal:  Mol Neurodegener       Date:  2021-02-22       Impact factor: 14.195

5.  Feasibility of postmortem examination in the era of COVID-19 pandemic: the experience of a Northeast Italy University Hospital.

Authors:  Cristina Basso; Fiorella Calabrese; Marta Sbaraglia; Claudia Del Vecchio; Giovanni Carretta; Annamaria Saieva; Daniele Donato; Luciano Flor; Andrea Crisanti; Angelo Paolo Dei Tos
Journal:  Virchows Arch       Date:  2020-06-09       Impact factor: 4.535

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.